6-K: Report of foreign private issuer (related to financial reporting)
6-K: The 148th Interim Period Business Report
6-K: Semi-annual Securities Report
6-K: Earnings Report for the Six-month Period Ended September 30, 2024
6-K: Notice of the Revised Forecast of Consolidated Financials for FY2024
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
144: Notice of proposed sale of securities pursuant to Rule 144
SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4%),Takeda Ventures, Inc(4%)
6-K: Earnings Report for the Three-month Period Ended June 30, 2024
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
No Data